Sangamo Therapeutics Inc (SGMO) Stock Price Target 2026

See analyst price targets, ratings and recent upgrades and downgrades for Sangamo Therapeutics Inc (SGMO) stock.

Latest Upgrades and Downgrades for Sangamo Therapeutics Inc Stock

Date	Firm	Analyst	Action	Rating Change	Price Target
—	HC Wainwright & Co.	Patrick R. Trucchio	Maintained	Buy	$10
—	Barclays	Gena Wang	Downgrade	Overweight→Equal-Weight	$5→$1
—	HC Wainwright & Co.	Patrick R. Trucchio	Maintained	Buy	$10
—	HC Wainwright & Co.	Patrick Trucchio	Maintained	Buy	$10
—	Barclays	Gena Wang	PT Cut	Overweight	$9→$5
—	HC Wainwright & Co.	Patrick Trucchio	Maintained	Buy	$10
—	RBC Capital	Luca Issi	Maintained	Sector Perform	$2
—	HC Wainwright & Co.	Patrick Trucchio	Maintained	Buy	$10
—	Truist Securities	Nicole Germino	PT Cut	Buy	$7→$5
—	HC Wainwright & Co.	Patrick Trucchio	Maintained	Buy	$10
—	Jefferies	Maury Raycroft	PT Cut	Buy	$7→$3
—	Wells Fargo	Jim Birchenough	PT Cut	Equal-Weight	$3→$2
—	HC Wainwright & Co.	Patrick Trucchio	Maintained	Buy	$10
—	HC Wainwright & Co.	Patrick Trucchio	Maintained	Buy	$10
—	HC Wainwright & Co.	Patrick Trucchio	Maintained	Buy	$10
—	HC Wainwright & Co.	Patrick Trucchio	Maintained	Buy	$10
—	Barclays	Gena Wang	PT Raise	Overweight	$3→$9
—	HC Wainwright & Co.	Patrick Trucchio	PT Raise	Buy	$5→$10
—	HC Wainwright & Co.	Patrick Trucchio	Maintained	Buy	$5
—	HC Wainwright & Co.	Patrick Trucchio	Maintained	Buy	$5

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Sangamo Therapeutics, Maintains $10 Price Target

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Sangamo Therapeutics (NASDAQ:SGMO) with a Buy and maintains $10 price target.

Benzinga Newsdesk

This CarMax Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday

Avi Kapoor

PRO
Barclays Downgrades Sangamo Therapeutics to Equal-Weight, Lowers Price Target to $1

Barclays analyst Gena Wang downgrades Sangamo Therapeutics (NASDAQ:SGMO) from Overweight to Equal-Weight and lowers the price target from $5 to $1.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Sangamo Therapeutics, Maintains $10 Price Target

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Sangamo Therapeutics (NASDAQ:SGMO) with a Buy and maintains $10 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Sangamo Therapeutics, Maintains $10 Price Target

HC Wainwright & Co. analyst Patrick Trucchio reiterates Sangamo Therapeutics (NASDAQ:SGMO) with a Buy and maintains $10 price target.

Benzinga Newsdesk

PRO
Barclays Maintains Overweight on Sangamo Therapeutics, Lowers Price Target to $5

Barclays analyst Gena Wang maintains Sangamo Therapeutics (NASDAQ:SGMO) with a Overweight and lowers the price target from $9 to $5.

Benzinga Newsdesk

Sangamo Therapeutics Inc

Sangamo Therapeutics Inc (SGMO) Stock Price Target 2026

Latest Upgrades and Downgrades for Sangamo Therapeutics Inc Stock

Sangamo Therapeutics Inc (SGMO) Stock Price Target 2026

Latest Upgrades and Downgrades for Sangamo Therapeutics Inc Stock

Analyst Ratings News

PROHC Wainwright & Co. Reiterates Buy on Sangamo Therapeutics, Maintains $10 Price Target

This CarMax Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday

PROBarclays Downgrades Sangamo Therapeutics to Equal-Weight, Lowers Price Target to $1

PROHC Wainwright & Co. Reiterates Buy on Sangamo Therapeutics, Maintains $10 Price Target

PROHC Wainwright & Co. Reiterates Buy on Sangamo Therapeutics, Maintains $10 Price Target

PROBarclays Maintains Overweight on Sangamo Therapeutics, Lowers Price Target to $5

Analyst Ratings News

PROHC Wainwright & Co. Reiterates Buy on Sangamo Therapeutics, Maintains $10 Price Target

This CarMax Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday

PROBarclays Downgrades Sangamo Therapeutics to Equal-Weight, Lowers Price Target to $1

PROHC Wainwright & Co. Reiterates Buy on Sangamo Therapeutics, Maintains $10 Price Target

PROHC Wainwright & Co. Reiterates Buy on Sangamo Therapeutics, Maintains $10 Price Target

PROBarclays Maintains Overweight on Sangamo Therapeutics, Lowers Price Target to $5

PRO
HC Wainwright & Co. Reiterates Buy on Sangamo Therapeutics, Maintains $10 Price Target

PRO
Barclays Downgrades Sangamo Therapeutics to Equal-Weight, Lowers Price Target to $1

PRO
HC Wainwright & Co. Reiterates Buy on Sangamo Therapeutics, Maintains $10 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Sangamo Therapeutics, Maintains $10 Price Target

PRO
Barclays Maintains Overweight on Sangamo Therapeutics, Lowers Price Target to $5

PRO
HC Wainwright & Co. Reiterates Buy on Sangamo Therapeutics, Maintains $10 Price Target

PRO
Barclays Downgrades Sangamo Therapeutics to Equal-Weight, Lowers Price Target to $1

PRO
HC Wainwright & Co. Reiterates Buy on Sangamo Therapeutics, Maintains $10 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Sangamo Therapeutics, Maintains $10 Price Target

PRO
Barclays Maintains Overweight on Sangamo Therapeutics, Lowers Price Target to $5